Co-hosts Jörn Schattenberg, Louise Campbell and Roger Green convene to discuss what’s happening for fatty liver so far in 2023 and moving into the second quarter. In this conversation, Jörn describes his attendance at the 3rd Annual Liver Connect Conference in California.
This week, co-hosts Jörn Schattenberg, Louise Campbell and Roger Green discuss the 3rd Annual Liver Connect Conference, NICE approval process for FibroScan in primary care, updates in the therapeutic pipeline, pathways and the Surfing NASH 4th anniversary special. The session is fun and full of surprises – like a new metaphor from Roger to describe fatty liver disease.
On May 6 and 7 2022, over 100 NAFLD stakeholders convened in Barcelona and online for the inaugural Innovations in NAFLD Care 2022 conference (#INCBCN.) This episode comes from the Surfing NASH coverage and to preview the upcoming 2023 Workshop.
Surfing NASH previews the 2023 Innovations in NAFLD Care Workshop with conference founders and directors, Jeff Lazarus and Jörn Schattenberg. This final conversation investigates what sort of impact the Workshop will have in the imminent future and the factors that will determine its success.
Surfing NASH previews the 2023 Innovations in NAFLD Care Workshop with conference founders and directors, Jeff Lazarus and Jörn Schattenberg. This conversation explores qualities which set the event apart from others and expands on its interactive emphasis.
Surfing NASH previews the 2023 Innovations in NAFLD Care Workshop with conference founders and directors, Jeff Lazarus and Jörn Schattenberg. This conversation introduces themes and sessions from Day 2 in Barcelona, including a debate on diet: can vegetarianism cure NAFLD?
Surfing NASH previews the 2023 Innovations in NAFLD Care Workshop with conference founders and directors, Jeff Lazarus and Jörn Schattenberg. This conversation continues to introduce themes and sessions from Day 1 in Barcelona on May 26. The group dives in-dept to the linkage between Fatty Liver and cancers, and the importance of early liver health screening for cancer prevention.
Surfing NASH previews the 2023 Innovations in NAFLD Care Workshop with conference founders and directors, Jeff Lazarus and Jörn Schattenberg. This conversation highlights feedback from last year’s inaugural event and introduces sessions from this year’s opening in Barcelona on May 26.
Surfing NASH previews the 2023 Innovations in NAFLD Care Workshop with conference founders and directors, Jeff Lazarus and Jörn Schattenberg. The group discusses a uniquely focused event with powerful perspectives spanning across all stakeholders.
From the Vault: What unique challenges arise when building a disease model for NASH prevalence and what strategies do leading modelers use to overcome them?
In this final conversation the Surfers explore the impact they believe ICER’s draft report on resmetirom and obeticholic acid for NASH will have for different stakeholders. The panelists each touch on different perspectives to offer a well-rounded wrap-up.
The Surfers provide an analysis of a recent draft report from the Institute for Clinical and Economic Review (ICER) on resmetirom and obeticholic acid for NASH. In this conversation, the group explores the pros and cons of biopsy while critiquing the report’s position on the practice. Discussion goes on to consider challenges for payers trying to determine the economic impacts of these drugs.
The Surfers provide an analysis of a recent draft report from the Institute for Clinical and Economic Review (ICER) on resmetirom and obeticholic acid for NASH. In this conversation, the panelists discuss how to effectively collect and implement changes reflected by the explosion of data emerging from the NAFLD and NASH space.
The Surfers provide an analysis of a recent draft report from the Institute for Clinical and Economic Review (ICER) on resmetirom and obeticholic acid for NASH. In this conversation, Hannah Mamuszka, founder and CEO of Alva10, discusses the report’s assessment of disease prevalence and outlines payer perspectives on prospective drug efficacy.
The Surfers are joined by Jeff McIntyre of the Global Liver Institute, Veronica Miller of the Liver Forum and new guest, Hannah Mamuszka, who is founder and CEO of Alva10. This leading conversation provides an introduction to a draft report from the Institute for Clinical and Economic Review (ICER) on resmetirom and obeticholic acid for NASH.
The Surfers evaluate a draft report from the Institute for Clinical and Economic Review (ICER) on resmetirom and obeticholic acid for NASH. This high-caliber session offers a plethora of practical considerations around accessing approved NASH pharmacotherapies for those most in need.
Jörn Schattenberg, Louise Campbell, Stephen Harrison and Roger Green share “SurfingNASH predictions” of the most important events that will take place between the 5th and 6th International NASH Days.
This final segment with Jeff McIntyre of the Global Liver Institute (GLI) wraps up discussion around what’s happening in NAFLD and NASH for the first quarter of an exciting year. Roger Green invites the panelists to provide the most significant and optimistic thing they will be touching over the next three months followed by the greatest fear each has in the same space.
The Surfers are joined by Jeff McIntyre of the Global Liver Institute for a thought-provoking discussion on increasing incidence of Type-2 diabetes among adolescents. The group shares ideas around what’s contributing to this swelling burden and how to dampen its devastating impact.
The Surfers are joined by Jeff McIntyre of the Global Liver Institute for a thought-provoking session around bringing hepatology to the public health dinner table. This conversation explores what’s going on in the assessment of package nutrition labeling and fighting for fair regulation around what’s deemed “healthy.”
The Surfers are joined by Jeff McIntyre of the Global Liver Institute for a thought-provoking discussion around pricing estimates for imminent drug approvals and the future standard of NITs. This conversation elicits mixed responses ranging from positive excitement to head-scratching concern.
Jörn Schattenberg, Louise Campbell and Roger Green discuss what’s happening thus far for the Fatty Liver field in 2023. The panelists touch on topics ranging from trials with non-invasive endpoints to guidelines, guidances and cross-specialty screening for liver health.
The Surfers are joined by Jeff McIntyre of the Global Liver Institute for a thought-provoking impromptu session on what’s happening thus far for the Fatty Liver field in 2023. They discuss emerging stories in science and policy which elicit responses ranging from positive excitement to head-scratching concern.
This conversation From the Vault visits the 2022 Liver Conference coverage of pediatric NASH and NAFLD with guest, Naim Alkhouri.
In this final conversation on pediatric and adolescent Fatty Liver disease, the Surfers conclude thoughts around putting a stop to the momentum amassing dire complications in a vulnerable population.
The Surfers discuss the timely cost of waiting for clinical trial results to be applied to real world settings. This conversation also introduces ideas around the necessary considerations for prescribing therapies to adolescents when lifestyle interventions fail to halt disease progression.
The Surfers explore the metabolic implications behind patients living longer with Fatty Livers. Guests Naim Alkhouri and Rohit Kohli go on to describe the unique challenges associated with use of NITs in the pediatric population.
The Surfers discuss increasing incidence of pediatric and adolescent Fatty Liver disease. This is a sobering session which introduces a critical issue intimate to two extremely knowledgeable guests, Naim Alkhouri and Rohit Kohli.
The Surfers investigate pediatric and adolescent Fatty Liver disease, its alarming prevalence and developing the field’s understanding around how to treat a vulnerable subpopulation. This is a special session which illuminates a critical issue intimate to two extremely knowledgeable guests, Naim Alkhouri and Rohit Kohli.
In this episode From the Vault, Jeff Lazarus and Roger Green discuss the ease of creating valuable metrics in a comprehensive care model, while our three practitioners — Stephen Harrison, Jörn Schattenberg and Louise Campbell — dive further into how they believe this model will improve care.
In this preview of the Season 2 debut of the Rising Tide series for healthcare professionals who treat diabetic patients, the patients themselves and their caregivers, co-hosts Ken Cusi and Roger Green are joined by Mazen Noureddin to talk about prevalence and taking action on the frontlines today.
This week, SurfingNASH.com is offering conversation previews from our new series, “The NASH Tsunami in Diabetes; Getting Ahead of the Rising Tide.”
This week, SurfingNASH.com is offering conversation previews from our new series, “The NASH Tsunami in Diabetes; Getting Ahead of the Rising Tide.”
In a preview of the premier episode of The NASH Tsunami in Diabetes: Getting Ahead of the Rising Tide, key opinion leaders Doctors Stephen Harrison, Kathleen Corey and Kay Pepin join co-hosts Dr. Ken Cusi and Roger Green to discuss key issues related to the NAFLD-Diabetes Link.
This week, SurfingNASH.com is offering a 17-minute section of our new series, “The NASH Tsunami in Diabetes; Getting Ahead of the Rising Tide.” Rising Tide, as we call it, is a subscription-only series targeted at the primary care physicians, endocrinologists and allied health professionals who provide front-line treatments for patients living with Type 2 Diabetes and/or obesity.
Learn about the amazingly diverse and exciting program for Day Two of the inaugural Innovations in NAFLD Care 2022 Workshop, with sessions on Comprehensive Care pathways, current and future pharmacotherapies, and what a future integrated treatment roadmap might look like.
The podcast ventures into the emergence of digital therapeutics with Joe Rubinsztain, CEO and Co-Founder of ChronWell, and Mark Berman, CMO of Better Therapeutics. In this final conversation, the panelists provide closing thoughts on the future of this space and how it may play out across different economic systems.
The podcast ventures into the emerging space of digital therapeutics with Joe Rubinsztain, CEO and Co-Founder of ChronWell, and Mark Berman, CMO of Better Therapeutics. The panelists consider regulatory challenges for prescribing digital therapeutics as an evidence-based treatment. Additionally, Louise Campbell introduces a free lifestyle app that she is working on that aims to improve liver health.
Joe Rubinsztain, CEO and Co-Founder of ChronWell, discusses scalable technology and the future of digital health. Within this context, the panelists consider the dynamics of insurers, providers and building an understanding around the full spectrum of disease treatment.
Naim Alkhouri shares his experience conducting a feasibility study with Better Therapeutics aimed at improving liver health through use of an app. The panelists discuss cognitive behavioral therapy, noninvasive technologies, assessing endpoints and much more.
The podcast ventures into the emerging digital therapeutics space with Joe Rubinsztain, CEO and Co-Founder of ChronWell, and Mark Berman, CMO of Better Therapeutics. In this conversation, both guests share their unique backgrounds and paths to combating Fatty Liver through technological innovation.
For the first time, Surfing NASH takes a deep dive into the prospect of digital therapeutics, their ability to drive outcomes and the critical success factors for proper use and deployment.
Lead author Jeffrey Lazarus and co-author Jörn Schattenberg join Stephen Harrison, Louise Campbell and Roger Green to discuss the groundbreaking paper “Advancing the Global Health Agenda for NAFLD.” This conversation focuses on the question “What’s Next,” which makes the scale of the challenge clear and compelling.
AASLD has published new practice guidance on the clinical assessment and management of NAFLD. Surfers Jörn Schattenberg, Louise Campbell and Roger Green are joined by Ken Cusi to discuss a new Rising Tide podcast series and final thoughts on the guidance document.
AASLD has published new practice guidance on the clinical assessment and management of NAFLD. Surfers Jörn Schattenberg, Louise Campbell and Roger Green are joined by Ken Cusi to discuss its influence outside of the US.
AASLD has published new practice guidance on the clinical assessment and management of NAFLD. Surfers Jörn Schattenberg, Louise Campbell and Roger are joined by Ken Cusi to discuss the document’s practical impact on patients today.
AASLD has published new practice guidance on the clinical assessment and management of NAFLD. Surfers Jörn Schattenberg, Louise Campbell and Roger Green are joined by Ken Cusi to discuss ALT cut off and utlizing FIB-4 in primary care.
AASLD has published new practice guidance on the clinical assessment and management of NAFLD. Surfers Jörn Schattenberg, Louise Campbell and Roger Green are joined by Ken Cusi to explore the document’s key features and provide a high-level introduction.
AASLD has published new practice guidance on the clinical assessment and management of NAFLD. Surfers Jörn Schattenberg, Louise Campbell and Roger Green are joined by Ken Cusi to explore its key features and implications which place emphasis on advances in noninvasive risk stratification and therapeutics.
In this episode From the Vault, Patient advocates Achim Kautz and Andrew Scott join the Surfers to discuss the role of NAFLD patient advocacy in the Fatty Liver community. This conversation centers around the importance of taking action locally and enhancing communication across stakeholder groups if we are to keep increasing momentum over time.
The podcast heads Down Under as Louise Campbell hosts this week’s surf with Brisbane-based guest, Tony Rahman. This final conversation examines Australia’s positioning to distribute limited resources in response to accessing expensive new drugs. As the session winds down, Tony offers his vision for what the next 2-3 years holds for Fatty Liver in Australia.
The podcast heads Down Under as Louise Campbell hosts this week’s surf with Brisbane-based guest, Tony Rahman. In this conversation they explore use of FIB-4 and FibroScan, linking cardiovascular outcomes to Fatty Liver and establishing new systems to improve accessibility of care.
The podcast heads Down Under as Louise Campbell hosts this week’s surf with Brisbane-based guest, Tony Rahman. In this conversation they discuss NAFLD and NASH subpopulations in Australia, and innovative approaches to providing for a large number of rural patients.
The podcast heads Down Under as Louise Campbell hosts this week’s surf with Brisbane-based guest, Tony Rahman. After Tony outlines a career trajectory and how he arrived at the frontlines of NAFLD and NASH in Australia, the duo discuss themes focused around public health and prevalence.
The podcast heads Down Under as Louise Campbell hosts this week’s surf from Australia. Joining her is Brisbane-based Director of Gastroenterology & Hepatology at The Prince Charles Hospital, Tony Rahman. The two discuss NAFLD and NASH prevalence, providing for rural populations, FibroScan, FIB-4 and the future of combating Fatty Liver in Australia.
This episode From the Vault comes from Season 3, Episode 39.4. Ian Rowe’s decision curve model does an excellent job of modeling the success rate and cost effectiveness of modeling early NASH diagnosis. However, as Louise Campbell points out, simply getting the patient diagnosed does not mean therapeutic success, which has implications for the early diagnosis model and broader patient management issues.
Tim Jobson of Predictive Health Intelligence joins the podcast to introduce analyzing historic blood test results to identify those at risk of Fatty Liver disease. In this final conversation, panelists revisit themes of data aggregation, data transparency, patient feedback and more. Surf on to listen to their concluding remarks and learn about the future of the project.
Tim Jobson of Predictive Health Intelligence joins the podcast to introduce analyzing historic blood test results to identify those at risk of Fatty Liver disease. In this conversation, panelists focus on the dual issues of patient data security and proactivity for better health outcomes.
Tim Jobson of Predictive Health Intelligence joins the podcast to introduce analyzing historic blood test results to identify those at risk of Fatty Liver disease. In this conversation, panelists explore various areas of application where the Predictive Health tool may be of significant value.
Tim Jobson of Predictive Health Intelligence joins the podcast to introduce analyzing historic blood test results to identify those at risk of Fatty Liver disease. In this conversation, he fields questions from the co-hosts around how the system fundamentally works and its economic value proposition to the NHS.
Tim Jobson of Predictive Health Intelligence joins the podcast to introduce analyzing historic blood test results to identify those at risk of Fatty Liver disease. In this conversation, he shares insights from creating a “combined informatics and clinical program simultaneously.”
In this episode, Tim Jobson, founder of Predictive Health Intelligence, joins the co-hosts to discuss analyzing historic blood test results to identify those at risk of Fatty Liver disease. He shares insights from building a project which is a “combined informatics and clinical program simultaneously,” all while fielding questions from Jörn Schattenberg, Louise Campbell and Roger Green on a subject particularly pertinent to the podcast.
Surfing NASH highlights key moments from its coverage of a watershed moment for Fatty Liver at NASH-TAG 2023. In this conversation, Donna Cryer and Roger Green share impressions from the regulatory viewpoint.
Surfing NASH highlights key moments from its coverage of a watershed moment for Fatty Liver at NASH-TAG 2023. In this conversation, patient advocates Michael Betel and Tony Villiotti join Louise Campbell and Roger Green to share impressions from a momentous conference.
This week’s conversation series continues on the theme of reviewing NASH-TAG 2023, a watershed moment for Fatty Liver disease. For this wrap-up feature, Amy Articolo and Naim Alkhouri join Jörn Schattenberg and Roger Green to illustrate their enthusiasm coming out of the conference.
